ApoVax
Louisville, Kentucky, United States
About ApoVax
ApoVax, Inc., a biotechnology company, develops immunotherapies for regulating the immune system to fight against diseases. Its products include ApoVax104, a recombinant protein vaccine that combines with antigens, tumors, and infectious disease markers and stimulates an immune response to create a disease-specific vaccine or therapeutic; and ProtEx, a technology that enables recombinant immunoregulatory proteins to be placed on the surface of cells, tissues, organs, and synthetic surfaces to modulate the immune system. The company’s products also include ApoVax104-HPV, a therapeutic vaccine for cervical cancer and human papillomavirus infection in women. In addition, its research programs c...
Company Facts
- Operating status: Active
- Company type: For Profit
- IPO status: Private
- Employees: 1 – 10
- Estimated revenue: Less than $1M
- Total funding: $375.0K
- Last round: Debt Financing (Nov 2012)
- Website: apovax.com
- Phone: 5025691021
Industries & Categories
Biotechnology, Medical, Pharmaceutical
Social Profiles
Canonical: https://fsome.com/organization/apovax-2486499 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.